Key terms
About INBX
Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INBX news
Feb 29
12:30am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX) and Inhibrx (INBX)
Feb 28
7:39pm ET
Inhibrx downgraded to Hold from Buy at Jefferies
Feb 28
9:17am ET
Inhibrx reports Q4 EPS ($1.73), consensus ($1.04)
Jan 24
3:04am ET
Inhibrx Announces Execution of Merger Agreement
Jan 24
3:04am ET
Inhibrx Announces Merger and Spin-Off Agreements with Aventis
Jan 23
4:18pm ET
Inhibrx downgraded to Market Perform from Outperform at LifeSci Capital
Jan 23
4:15pm ET
Inhibrx’s Strategic Maneuvers and Market Prospects: A Balanced Hold Recommendation
Jan 23
5:31am ET
Inhibrx to sell INBRX-101 to Sanofi in $2.2B transaction
Jan 23
4:26am ET
Inhibrx downgraded to Market Perform from Outperform at JMP Securities
Jan 23
12:30am ET
Analysts Offer Insights on Healthcare Companies: Spruce Biosciences (SPRB) and Inhibrx (INBX)
No recent press releases are available for INBX
INBX Financials
Key terms
Ad Feedback
INBX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INBX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
